Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
30 September 2024 - 2:30PM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) products for cancer and autoimmune disease, today
announced that it will participate in panel focused on innovations
in the allogeneic cell therapy landscape during the Goldman Sachs
Cell Therapy Day on October 1, 2024 in New York.
Goldman Sachs Cell Therapy DayTuesday, October 1,
2024Panel Discussion: 10:00AM PT/1:00PM ET
A webcast of this panel discussion will be posted
to the Company's website at www.allogene.com under the
Investors tab in the News and Events section. Following a live
webcast, a replay will be available on the Company's website for
approximately 30 days.
About Allogene
TherapeuticsAllogene Therapeutics, with headquarters
in South San Francisco, is a clinical-stage biotechnology
company pioneering the development of allogeneic chimeric antigen
receptor T cell (AlloCAR T™) products for cancer and
autoimmune disease. Led by a management team with
significant experience in cell therapy, Allogene is developing
a pipeline of “off-the-shelf” CAR T cell product candidates
with the goal of delivering readily available cell therapy
on-demand, more reliably, and at greater scale to more
patients. For more information, please visit www.allogene.com,
and follow Allogene Therapeutics on X (formerly Twitter)
and LinkedIn.
Cautionary Note on Forward-Looking
Statements for AllogeneThis press release contains
forward-looking statements for purposes of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements regarding intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things Allogene’s ability to develop and
deliver readily available allogeneic CAR T products for the
treatment of cancer and autoimmune disease on-demand, more
reliably, and at greater scale to more patients. Various factors
may cause material differences between Allogene’s expectations and
actual results, including risks and uncertainties related to our
product candidates being based on novel technologies, which makes
it difficult to predict the time and cost of product candidate
development, the safety or efficacy of a product candidate, and
whether a product candidate will receive regulatory approval, which
could prevent or delay commercialization. These and other risks are
discussed in greater detail in Allogene’s filings with
the SEC, including without limitation under the “Risk Factor”
heading in its Quarterly Report on Form 10-Q for the quarter
ended June 30, 2024. Any forward-looking statements that are
made in this press release speak only as of the date of this press
release. Allogene assumes no obligation to update the
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
AlloCAR T™ is a trademark of Allogene
Therapeutics, Inc.
Allogene Media/Investor
Contact:Christine CassianoEVP, Chief Corporate Affairs
& Brand Strategy OfficerChristine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
Von Okt 2023 bis Okt 2024